Join our daily newsletter At The Bell to receive exclusive market insights
- Recce Pharmaceuticals (RCE) has locked in agreements to assess its new spray-on antibiotic for topical burn wound treatment in a series of clinical trials
- The 30-patient trials are set to take place at Fiona Stanley hospital in Perth with the first candidates prepared to be tested in the current quarter
- More specifically, the study will assess the safety and efficacy of RECCE 327 against a broad range of infectious disease on chronic burn wounds
- “Based on promising results from preclinical studies, we believe RECCE 327 has potential to make a significant impact in treating infections,” commented Recce Pharmaceuticals Chairman Dr John Prendergast
- Recce is trading steady at $1.11 per share
Recce Pharmaceuticals (RCE) has locked in agreements to assess its new spray-on antibiotic for topical burn wound treatment in a series of clinical trials.
In an agreement with Fiona Stanely hospital’s burns unit in Perth, the study will assess RECCE 327’s safety and efficacy against a broad range of infectious disease on chronic burn wounds in up to 30 patients.
The first patients are set to be tested in the current quarter and the trial will take place over 14 days, with the first 10 receiving RECCE 327 daily and the remaining 20 to receive treatment three times per week.
The study is being overseen by three infectious disease and burns experts, namely Dr Edward Raby, Dr Chris Heath and Professor Fiona Wood.
Dr Raby said antibiotic resistant is a major issue after burns injuries.
“Our team is keen to identify and add new treatments with the potential to overcome antibiotic resistance and improve patient’s lives,” he explained.
The spray-on formulation has been specifically developed for the study and was produced at the company’s manufacturing facility to the same human clinical study standards as the previously announced in the phase one intravenous clinical trial.
Recce anticipates the two studies will run concurrently.
RECCE 327 was awarded Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act by the U.S. Food and Drug Administration, granting it fast track designation and 10 years of market exclusivity post-approval.
“We believe RECCE 327 has potential to make a significant impact in treating infections,” Recce Pharmaceuticals Chairman Dr John Prendergast said.
“We look forward to working with the world-leading team at Fiona Stanley Hospital in advancing new treatment options for burns victims at increased risk of infection from multidrug-resistant organisms,” he concluded.
Recce is trading steady at $1.11 per share at 10:15 am AEDT.
